Peptide YY Analogue (Cagrilintide Component)
Native GLP-1 (7-37) is the endogenous 31-aa incretin secreted by intestinal L-cells. It potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. The structural template for semaglutide, liraglutide, and exenatide.
Community Rating
No ratings yet
Compound Profile
Peptide YY Analogue (Cagrilintide Component)
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Peptide YY Analogue (Cagrilintide Component) is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Potentiates glucose-dependent insulin secretion from beta cells — the defining incretin mechanism
- Suppresses postprandial glucagon secretion from alpha cells — reduces hepatic glucose output
- Slows gastric emptying — modulates rate of nutrient absorption after meals
- Peptide YY Analogue (Cagrilintide Component) is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Potentiates glucose-dependent insulin secretion from beta cells — the defining incretin mechanism
- Suppresses postprandial glucagon secretion from alpha cells — reduces hepatic glucose output
- Slows gastric emptying — modulates rate of nutrient absorption after meals
- Reduces appetite via GLP-1R on hypothalamic neurons (arcuate nucleus) and area postrema
In Plain English
Simple summaryNative GLP-1 (glucagon-like peptide-1, specifically the 7-37 and 7-36 amide forms) is a 30-31 amino acid incretin hormone your small intestine releases within minutes of eating carbohydrates and fat. It does four things: stimulates insulin secretion in a glucose-dependent way (only when glucose is actually elevated), suppresses glucagon, slows gastric emptying, and signals satiety to the brain. The reason semaglutide, liraglutide, exenatide, and tirzepatide (half the drug) exist is that native GLP-1 is devastatingly short-lived -- it's inactivated by the DPP-4 enzyme within 2 minutes of release, making it essentially useless as a drug itself. Every GLP-1 drug is an engineered workaround for that degradation problem.
- Potentiates glucose-dependent insulin secretion from beta cells — the defining incretin mechanism
- Suppresses postprandial glucagon secretion from alpha cells — reduces hepatic glucose output
- Slows gastric emptying — modulates rate of nutrient absorption after meals
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Peptide YY Analogue (Cagrilintide Component)?
Tap any underlined term for an instant definition.
Native GLP-1 (Glucagon-Like Peptide-1, 7-37) is a 31-amino acid incretin hormone produced by post-translational processing of proglucagon in intestinal L-cells, enteric neurons, and the nucleus of the solitary tract in the brainstem. The biologically active forms are GLP-1(7-37) and GLP-1(7-36)amide; the latter is the predominant circulating form.
GLP-1 is secreted within 10-15 minutes of a meal in proportion to meal caloric content, with the fastest rise occurring in response to combined fat and carbohydrate intake. Its secretion is mediated by both direct L-cell stimulation (distal gut contact with nutrients) and neural (vagal) reflexes from proximal nutrient sensing.
**Mechanism of action via GLP-1R:** 1. **Pancreatic beta cells**: cAMP-mediated potentiation of KATP channel closure → depolarization → insulin secretion (glucose-dependent) 2. **Pancreatic alpha cells**: suppresses glucagon secretion (indirect, via somatostatin and direct alpha-cell GLP-1R) 3. **Stomach**: vagal GLP-1R activation slows gastric emptying 4. **Hypothalamus/brainstem**: GLP-1R in arcuate nucleus, paraventricular nucleus, and area postrema → satiety, nausea 5. **Heart**: GLP-1R on cardiomyocytes → cardioprotection (MACE reduction in cardiovascular outcome trials)
The critical limitation of native GLP-1 is its ~1-2 minute plasma half-life due to N-terminal DPP-IV cleavage at position 2 (His-Ala motif). This limitation drove the development of the entire GLP-1R agonist drug class — by modifying the His-Ala motif, extending the peptide, or attaching fatty acid chains for albumin binding, pharmaceutical companies produced once-daily and once-weekly injectable drugs (liraglutide, semaglutide, dulaglutide, exenatide ER) and even oral formulations (oral semaglutide).
GLP-1's research applications span metabolic disease, cardiovascular disease (LEADER, SUSTAIN-6, AMPLITUDE-O trials demonstrated cardiovascular protection), neurodegenerative disease (GLP-1R on dopaminergic neurons; liraglutide studied in Parkinson's disease), and non-alcoholic steatohepatitis (NASH).
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Peptide YY Analogue (Cagrilintide Component). See all Metabolic & Weight peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Native GLP-1 is used as a research reference standard in incretin studies. Clinical applications use long-acting analogues:
Research IV infusion: 0.75-1.5 pmol/kg/min continuous IV infusion for acute metabolic studies Exenatide (twice-daily): 5-10 mcg SC BID (reference GLP-1R agonist) Liraglutide: 0.6-1.8 mg SC daily Semaglutide (weekly): 0.5-2 mg SC weekly or 3-14 mg oral daily
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Native GLP-1 is exclusively used as a research tool in acute infusion studies. All clinical and translational research uses DPP-IV-resistant long-acting analogues.
What the research doesn't show
Native GLP-1 itself isn't useful therapeutically because of its 2-minute half-life, which is why this page is primarily educational rather than practical. The GLP-1 biology page exists to give context for understanding the analogues. People often ask whether 'boosting GLP-1 naturally' through diet (high protein, fiber, fermented foods) produces meaningful GLP-1 receptor stimulation -- the answer is: the native pulse does happen, but it's brief and mild compared to weekly semaglutide.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Peptide YY Analogue (Cagrilintide Component), covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Peptide YY Analogue (Cagrilintide Component) has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: potentiates glucose-dependent insulin secretion from beta cells — the defining incretin mechanism.
The most commonly reported side effect in research subjects is native glp-1 is rapidly degraded by dpp-iv enzyme — half-life ~1-2 minutes in plasma. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
DPP-4 inhibitors (sitagliptin, saxagliptin) block the enzyme that degrades GLP-1, raising native GLP-1 levels modestly. GLP-1 receptor agonists (semaglutide, liraglutide) bypass native GLP-1 entirely and bind the receptor directly with much longer duration. GIP is the other major incretin -- tirzepatide targets both GLP-1 and GIP receptors. Understanding native GLP-1 makes the pharmacology of the entire diabetes and obesity drug landscape much clearer.
Compare Peptide YY Analogue (Cagrilintide Component) side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.